Abstract
AbstractCarotid bodies (CBs) are chemoreceptors that monitor and register changes in the blood, including the levels of oxygen, carbon dioxide, and pH, and regulate breathing. Enhanced activity of CBs was shown to correlate with a significant elevation in the blood pressure of patients with hypertension. CB removal or denervation were previously shown to reduce hypertension. Here we demonstrate the feasibility of a dual-mode ultrasound array (DMUA) system to safely ablate the CB in vivo in a spontaneously hypertensive rat (SHR) model of hypertension. DMUA imaging was used for guiding and monitoring focused ultrasound (FUS) energy delivered to the target region. In particular, 3D imaging was used to identify the carotid bifurcation for targeting the CBs. Intermittent, high frame rate imaging during image-guided FUS (IgFUS) delivery was used for monitoring the lesion formation. DMUA imaging provided feedback for closed-loop control (CLC) of the lesion formation process to avoid overexposure. The procedure was tolerated well in over 100 SHR and normotensive rats that received unilateral and bilateral treatments. The measured mean arterial pressure (MAP) exhibited measurable deviation from baseline 2–4 weeks post IgFUS treatment. The results suggest that the direct unilateral FUS treatment of the CB might be sufficient to reduce the blood pressure in hypertensive rats and justify further investigation in large animals and eventually in human patients.
Funder
International Cardio Corporation
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Benjamin, E. J. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135, e146–e603 (2017).
2. Swieton, D. et al. Visualizing carotid bodies with doppler ultrasound versus CT angiography: preliminary study. AJR American journal of roentgenology 209, 1348–1352 (2017).
3. Food. and Drug Administration and the Department of Health and Human Services. Notice. Guidance for Industry on Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims. 76 FR 14024, 1–12, https://www.fda.gov/downloads/Drugs/…/Guidances/ucm075072.pdf (2011). Accessible at.
4. Chobanian, A. V., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. et al. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206–1252 (2013).
5. Calhoun, D. A. et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 63, 451–458 (2014).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献